Back to Journals » Lung Cancer: Targets and Therapy » Volume 8

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib

Total article views   HTML views PDF downloads Totals
11,596 Dovepress* 8,248+ 1,324 9,572
PubMed Central* 3,348 473 3,821
Totals 11,596 1,797 13,393
*Since 13 October 2017
Total mentioned Facebook Delicious Reddit Twitter Others
5 1 0 0 0 4

View citations on PubMed Central and Google Scholar